País: Canadá
Língua: inglês
Origem: Health Canada
METHOTREXATE (METHOTREXATE SODIUM)
MEDEXUS PHARMACEUTICALS INC.
L01BA01
METHOTREXATE
7.5MG
SOLUTION
METHOTREXATE (METHOTREXATE SODIUM) 7.5MG
INTRA-ARTERIAL
0.75ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0107545004; AHFS:
CANCELLED POST MARKET
2022-06-29
_ _ _Page 1 of _38_ _ PRODUCT MONOGRAPH Pr METOJECT ® methotrexate sodium solution for injection methotrexate 10 mg/mL Single-Use Pre-Filled Syringes Sterile THERAPEUTIC CLASSIFICATION Antirheumatic Medexus Inc. 35 Nixon Road, Unit 1 Bolton, Ontario L7E 1K1 Submission Control No.: 237592 Date of Revision: May 22, 2020 _ _ _Page 2 of _38_ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........... Error! Bookmark not defined. SUMMARY PRODUCT INFORMATION ...................... ERROR! BOOKMARK NOT DEFINED. INDICATIONS AND CLINICAL USE ............................ ERROR! BOOKMARK NOT DEFINED. CONTRAINDICATIONS ................................................. ERROR! BOOKMARK NOT DEFINED. WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS .................................................. ERROR! BOOKMARK NOT DEFINED. DRUG INTERACTIONS ..................................................................................................16 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................30 ACTION AND CLINICAL PHARMACOLOGY ............................................................30 STORAGE AND STABILITY ..........................................................................................33 SPECIAL HANDLING INSTRUCTIONS .......................................................................33 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................34 PART II: SCIENTIFIC INFORMATION ...............................................................................35 PHARMACEUTICAL INFORMATION ..........................................................................35 DETAILED PHARMACOLOGY .....................................................................................36 TOXICOLOGY ......................................... Leia o documento completo